Company Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 04:10:18 18/07/25 pm AEST			5-day change	1st Jan Change
25.26 ^AUD	+2.77%		+4.86%	+2.64%

10/07	Telix Pharmaceuticals Limited Receives Permanent HCPCS Code for Gozellix from U.S. Centers for Medicare & Medicaid Services	CI
09/07	Telix's Prostate Cancer Imaging Agent Gozellix Secures US Reimbursement Code, Shares Up 6%	MT

Business description: Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Its segments include commercial, product development, medical technologies, and manufacturing services. Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX101, TLX300, TLX66, TLX66-CDx, and TLX090, among others.

Number of employees: 423

Sales by Activity: Telix Pharmaceuticals Limited

Fiscal Period: December	2020	2021	2022	2023	2024
Precision Medicine	-	-	-	-	771M
Therapeutics	-	-	-	-	9.35M
Manufacturing Solutions	-	-	-	-	2.75M
Product Development	-	-	3.73M	5.5M	-
Commercial	-	-	156M	497M	-
Pharmaceuticals	5.21M	7.6M	-	-	-

See all business segments

Geographical breakdown of sales: Telix Pharmaceuticals Limited

Fiscal Period: December	2020	2021	2022	2023	2024
United States	-	-	-	490M	762M
Other Countries	-	-	2.5M	4.67M	16.01M
Canada	-	-	-	-	2.54M
Australia	5.21M	7.6M	149K	1.17M	1.22M
United Kingdom	-	-	2.04M	1.31M	579K
Belgium	-	-	564K	458K	546K
U.s.	-	-	150M	-	-
China	-	-	3.35M	5.29M	-
Austria	-	-	1.48M	-	-

See all geographic segments

Executive Committee: Telix Pharmaceuticals Limited

Manager	Title	Age	Since
Christian Behrenbruch CEO	Chief Executive Officer	50	03/01/2017
Darren Smith DFI	Director of Finance/CFO	59	31/07/2022
Michael Wheatcroft CTO	Chief Tech/Sci/R&D Officer	-	-
David Cade CTO	Chief Tech/Sci/R&D Officer	56	01/01/2024
Paul Schaffer CTO	Chief Tech/Sci/R&D Officer	-	07/04/2025

See TELIX PHARMACEUTICALS LIMITED governance

Composition of the Board of Directors: Telix Pharmaceuticals Limited

Director	Title	Age	Since
Christian Behrenbruch BRD	Director/Board Member	50	03/01/2017
Mark Nelson BRD	Director/Board Member	65	17/09/2017
Jann Skinner BRD	Director/Board Member	67	19/06/2018
Tiffany Olson CHM	Chairman	65	21/05/2025
Marie McDonald BRD	Director/Board Member	69	03/03/2025

Composition of the Board of Directors

Shareholders: Telix Pharmaceuticals Limited

Name	Equities	%	Valuation
Andreas Kluge 6.729 %	22,675,000	6.729 %	363 M $
Christian Behrenbruch 6.3 %	21,228,298	6.3 %	340 M $
GRAND PHARMACEUTICAL GROUP LIMITED 3.249 %	10,947,181	3.249 %	175 M $
UV-Cap Verwaltungs GmbH 1.611 %	5,427,233	1.611 %	87 M $
State Street Bank & Trust Co. 1.511 %	5,090,739	1.511 %	81 M $

Name	Equities	%	Valuation
ABC ARBITRAGE 0.007997 %	26,939	0.007997 %	432 910 $
Private Advisor Group LLC 0.00301 %	10,140	0.00301 %	162 950 $
Morgan Stanley Capital Services LLC 0.001672 %	5,634	0.001672 %	90 538 $
UBS Financial Services, Inc. 0.001084 %	3,651	0.001084 %	58 672 $
RhumbLine Advisers LP 0.00034 %	1,146	0.00034 %	18 416 $

List of TELIX PHARMACEUTICALS LIMITED shareholders

Company details: Telix Pharmaceuticals Limited

Telix Pharmaceuticals Ltd.

55 Flemington Road Suite 401

3051, Melbourne

http://www.telixpharma.com

address Telix Pharmaceuticals Limited(TLX)

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
TELIX PHARMACEUTICALS LIMITED	+2.77%	+4.86%	+29.74%	+329.59%	5.39B
LONZA GROUP AG	-0.04%	+1.03%	+10.09%	+1.28%	50.03B
BEONE MEDICINES LTD.	+1.45%	+17.68%	+93.74%	+70.52%	34.39B
CELLTRION, INC.	-0.06%	+0.95%	+4.78%	+11.89%	28.64B
IQVIA HOLDINGS INC.	-1.60%	-1.33%	-28.56%	-24.54%	28.24B
EUROFINS SCIENTIFIC SE	+1.19%	+1.25%	+26.23%	-21.75%	12.59B
ICON PUBLIC LIMITED COMPANY	-2.27%	-4.64%	-56.21%	-29.79%	11.67B
ASCENDIS PHARMA A/S	-4.12%	-2.89%	+24.45%	+98.71%	10.73B
TEMPUS AI, INC.	+0.54%	+7.21%	+51.92%	-	10.5B
QIAGEN N.V.	+0.25%	+0.48%	+12.53%	-1.16%	10.45B
Average	-0.25%	+1.47%	+16.87%	+48.31%	20.26B
Weighted average by Cap.	-0.19%	+2.89%	+18.91%	+22.59%